Bundibugyo Virus Disease Outbreak in Uganda

Bundibugyo Virus Disease Alert: Uganda

Situation Overview

Uganda is currently experiencing an outbreak of Bundibugyo virus disease (BVD), a rare form of Ebola virus disease caused by infection with the Bundibugyo ebolavirus. This represents a Level 1 CDC travel health alert, indicating sustained transmission and ongoing public health concern.

About Bundibugyo Virus Disease

Bundibugyo virus is one of six known Ebola virus species. While less frequently documented than other Ebola strains, BVD causes similar hemorrhagic fever symptoms including:

  • High fever and malaise
  • Headache, myalgia, and weakness
  • Rash (typically appearing 5-7 days after symptom onset)
  • Vomiting, diarrhea, and abdominal pain
  • Impaired kidney and liver function
  • In severe cases, internal and external bleeding

Incubation period ranges from 2-21 days following exposure.

Risk to Travelers

The risk to international travelers remains low provided basic precautions are observed. Transmission occurs through direct contact with blood or body fluids of infected persons or animals, or contact with surfaces contaminated by these fluids. Person-to-person transmission requires direct contact with bodily fluids or indirect contact through contaminated materials.

Traveler Guidance

  • Monitor CDC and WHO travel advisories regularly
  • Avoid contact with blood and body fluids of sick persons
  • Avoid handling or consuming bushmeat
  • Practice rigorous hand hygiene and use alcohol-based sanitizers when soap unavailable
  • Seek immediate medical care at recognized facilities if fever develops during or within 21 days after travel
  • Inform healthcare providers of travel history

Healthcare Considerations

Travelers with pre-existing medical conditions or taking chronic medications should consult healthcare providers before traveling to affected regions regarding risk-benefit assessment and contingency planning.

Pharmacist's Note: No specific antiviral prophylaxis exists for Ebola prevention in travelers. Post-exposure prophylaxis (PEP) may be available in limited settings for documented high-risk exposures; this requires immediate medical evaluation at a facility equipped for Ebola management. Travel health insurance with medical evacuation coverage is strongly recommended. Travelers should maintain current vaccination records for routine immunizations and consult travel clinics ≥4-6 weeks before departure for personalized risk assessment. Information on supportive care medications and antimalarial chemoprophylaxis (if indicated) should be discussed with travel medicine specialists.

Resources

Primary sources

PharmTrip may include promotional content. Products and services are independently evaluated by a licensed pharmacist and rankings are never altered by advertiser requests. Information reflects what was current at the time of writing — please verify the latest terms on each provider's official site.